NASDAQ:TRDA
Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc.'s revenue fell 87.9% in fiscal 2025 to $25.4M while operating margin fell to −621.1%, its lowest in 3 years. Free cash flow was −$129.6M, −509.6% of revenue, and the diluted share count rose 6.1%.Summary generated from Entrada Therapeutics, Inc.'s SEC filings. Latest annual report filed Feb 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$25.4M
Revenue growth−87.9%
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating margin−621.1%
Net margin−565.5%
ROICn/a
Return on equity−39.1%
Debt / equityn/a
Free cash flow−$129.6M
FCF margin−509.6%
Share count change+6.1%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | 129 | 211 | 25 |
| Operating income | −51 | −97 | −3 | 47 | −158 |
| Net income | −51 | −95 | −7 | 66 | −144 |
| Free cash flow | −55 | −97 | 134 | −45 | −130 |
Recent filings
- 4Insider transaction report
Sep 9, 2026 - 4Insider transaction report
Sep 9, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 5, 2026 - 8-KResults of operations and financial condition
Aug 5, 2026 - 8-KDirector or officer change
Jun 10, 2026 - 8-KRegulation FD disclosure
May 19, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 7, 2026 - 8-KResults of operations and financial condition
May 7, 2026